Perhaps investors at the breakout session will raise this issue with Roy.
It's imperative for Squalamine to be manufactured on a consistent basis, in quality and quantity, GENR also needs secure manufacturing runs. GENR does not need to be dependent on a contract manufacturer who cannot provide the drug adequately when advancing into pivotals.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.